Astellas completes acquisition of Audentes TherapeuticsChristian Fernsby ▼ | January 16, 2020
Astellas Pharma announced that it has successfully completed the previously announced acquisition of Audentes Therapeutics.
Topics: Astellas acquisition Audentes Therapeutics
Astellas commenced the Tender Offer on December 16, 2019, New York City time, and the Tender Offer expired at 12:00 midnight, New York City time, at the end of the day on January 14, 2020.
As of the expiration of the Tender Offer, 35,852,857 shares of Audentes common stock were validly tendered and not properly withdrawn, representing approximately 76.7% of the shares of Audentes common stock outstanding, and such shares have been accepted for payment under the terms of the Tender Offer. ■